BELITE BIO, INC
BLTEDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Aug 10, 2026
7dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
BLTE Earnings Report
EPS Est: $-0.73 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tinlarebant | Phase 3 | STGD1 | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BELITE BIO, INC's drug pipeline?→
CatalystAlert tracks 1 drug candidate in BELITE BIO, INC's (BLTE) pipeline across Phase 3. Its lead program is Tinlarebant (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BELITE BIO, INC's next FDA catalyst?→
BELITE BIO, INC's (BLTE) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BLTE biotech catalysts?→
Add BLTE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BELITE BIO, INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.